Konstantinos Tryfonidis
- Oncology top 2%
- Cancer Research top 2%
- Pulmonary and Respiratory Medicine top 5%
- Molecular Biology
- Pathology and Forensic Medicine top 5%
- Co-authors
- Fátima CardosoDimitrios ZardavasElżbieta SenkusMartine PiccartLeen SlaetsJavier CortésMaria João CardosoRebecca Dent
- Topics
- Breast Cancer Treatment Studies (28 papers)Advanced Breast Cancer Therapies (18 papers)HER2/EGFR in Cancer Research (18 papers)
- Partner nations
- BelgiumUnited StatesPortugal
In The Last Decade
Konstantinos Tryfonidis
53 papers receiving 1.7k citations
Hit Papers
Peers
Comparison fields: 5 of 84
- Oncology 1.1k
- Cancer Research 771
- Pulmonary and Respiratory Medicine 406
- Molecular Biology 326
- Pathology and Forensic Medicine 233
Countries citing papers authored by Konstantinos Tryfonidis
This map shows the geographic impact of Konstantinos Tryfonidis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Konstantinos Tryfonidis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Konstantinos Tryfonidis more than expected).
Fields of papers citing papers by Konstantinos Tryfonidis
This network shows the impact of papers produced by Konstantinos Tryfonidis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Konstantinos Tryfonidis. The network helps show where Konstantinos Tryfonidis may publish in the future.
Co-authorship network of co-authors of Konstantinos Tryfonidis
This figure shows the co-authorship network connecting the top 25 collaborators of Konstantinos Tryfonidis. A scholar is included among the top collaborators of Konstantinos Tryfonidis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Konstantinos Tryfonidis. Konstantinos Tryfonidis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522breakdown → | 47 |
| 2 | 2 | |
| 3 | 5 | |
| 4 | 1 | |
| 5 | 20 | |
| 6 | 67 | |
| 7 | 1 | |
| 8 | 8 | |
| 9 | Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 studybreakdown → | 279 |
| 10 | 4 | |
| 11 | 1 | |
| 12 | 81 | |
| 13 | 10 | |
| 14 | 10 | |
| 15 | 2 | |
| 16 | 68 | |
| 17 | 98 | |
| 18 | 2 | |
| 19 | 116 | |
| 20 | 8 |
About Konstantinos Tryfonidis
Konstantinos Tryfonidis is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 53 papers that have together received 1.7k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (28 papers), Advanced Breast Cancer Therapies (18 papers) and HER2/EGFR in Cancer Research (18 papers). The work is most often cited by research in Cancer Research (771 citations), Oncology (1.1k citations) and Pathology and Forensic Medicine (233 citations). Konstantinos Tryfonidis has collaborated with scholars based in Belgium, United States and Portugal. Frequent co-authors include Fátima Cardoso, Dimitrios Zardavas, Elżbieta Senkus, Martine Piccart, Leen Slaets, Javier Cortés, Maria João Cardoso, Rebecca Dent, Benita S. Katzenellenbogen and Y.H. Park. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.